CliffBio
small molecule

LAMOTRIGINE

LAMOTRIGINE

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameLAMOTRIGINE
Active ingredientLAMOTRIGINE
Strength250MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2024
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.